It has been well established that women with certain genetic mutations (e.g. BRCA1 and BRCA2 mutations) have a predisposition towards some types of cancer. This paper considers the risks related to particular gene mutations, the changing role of genetic testing and the options for reducing or managing the risk of cancer.
This Scientific Impact Paper was developed prior to the emergence of the COVID-19 coronavirus.
This is the first version of this paper. Please note that the Scientific Advisory Committee regularly assesses the need to update. Further information on this review is available on request.
Developer declaration of interests.